Press coverage about Neos Therapeutics (NASDAQ:NEOS) has trended somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Neos Therapeutics earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned news stories about the company an impact score of 47.3093968407659 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Zacks: Analysts Expect Neos Therapeutics, Inc. (NEOS) Will Announce Earnings of -$0.60 Per Share (americanbankingnews.com)
- Neos Therapeutics, Inc. (NEOS) Posts Quarterly Earnings Results, Beats Estimates By $0.22 EPS (americanbankingnews.com)
- PDL BioPharma’s Proposal to Acquire Neos Therapeutics Expires Today; PDL Urges Neos to Provide Update on Sale … – PR Newswire (press release) (prnewswire.com)
- Neos Therapeutics to Present at the Stifel 2017 Healthcare Conference – GlobeNewswire (press release) (globenewswire.com)
- Why Neos Therapeutics Inc Rose 13.7% In October – Motley Fool (fool.com)
Several equities research analysts have recently issued reports on NEOS shares. Zacks Investment Research cut Neos Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 12th. Cantor Fitzgerald set a $20.00 price objective on Neos Therapeutics and gave the stock a “buy” rating in a report on Wednesday, November 1st. Wells Fargo & Company set a $14.00 price objective on Neos Therapeutics and gave the stock a “buy” rating in a report on Wednesday, October 18th. Cowen and Company restated a “buy” rating on shares of Neos Therapeutics in a report on Thursday, October 26th. Finally, Royal Bank Of Canada set a $12.00 price objective on Neos Therapeutics and gave the stock an “outperform” rating in a report on Tuesday, August 8th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $14.00.
Shares of Neos Therapeutics (NASDAQ NEOS) traded up $0.12 during trading on Monday, reaching $10.42. The company had a trading volume of 415,800 shares, compared to its average volume of 1,192,932. Neos Therapeutics has a 52-week low of $4.85 and a 52-week high of $13.15. The company has a debt-to-equity ratio of 2.33, a quick ratio of 2.84 and a current ratio of 3.04.
Neos Therapeutics (NASDAQ:NEOS) last issued its earnings results on Wednesday, November 8th. The company reported ($0.58) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.80) by $0.22. Neos Therapeutics had a negative return on equity of 580.51% and a negative net margin of 339.52%. The firm had revenue of $6.70 million for the quarter. equities research analysts predict that Neos Therapeutics will post -2.89 EPS for the current year.
TRADEMARK VIOLATION WARNING: This piece was first posted by Markets Daily and is the property of of Markets Daily. If you are accessing this piece on another website, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be viewed at https://www.themarketsdaily.com/2017/11/14/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-neos-therapeutics-neos-stock-price.html.
About Neos Therapeutics
Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).
Receive News & Ratings for Neos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.